Abstract 2080P
Background
ICIN is a major cause of death in cancer patients (pts). We aimed at identifying incidence of ICIN and predictors of poor prognosis in oncology.
Methods
We designed a multicenter retrospective cohort study on the Greater Paris University Hospitals' (APHP) clinical data warehouse. We included all adult pts with solid cancer hospitalized between January 2016 and December 2021 at APHP with an ICD-10 cancer code, with chemotherapy (chemo) within 30 days prior to the 1st ICIN (defined by the D70 or D611 ICD-10 codes AND a neutrophil count < 500/mm3). The primary outcome was the composite of Intensive Care Unit (ICU) hospitalization or death within 30 days. We collected cancer and chemo characteristics, use of G-CSF, Charlson score items and standard biological values.
Results
Among 141,586 cancer pts, 40,660 received chemo among whom 661 (1.6%) had ICIN. Their median age was 63 years (Interquartile Range (IQR) 54-70) and 330 (50%) were female. The median Charlson score was 10 (IQR 8-11). Documented bacterial or fungal infections were observed in 113 (17%) and 19 (3%) pts, respectively. Main primary cancers were lung (n= 204, 31%) and breast (n=87, 13%). Advanced cancers were present in 551 (83%) pts. The last chemo included platinum in 375 (57%) pts, 331 (50%) were in their 1st line of chemo and 284 (43%) in their 1st cycle of the current line, 149 (23%) had primary prophylactic G-CSF, 27 (4%) had a concomitant SarsCov2 infection. Primary outcome occurred in 120/661 (18%) pts: 57 (9%) were transferred to intensive care and 82 (12%) died within 30 days. After ICIN, 372 (56%) pts received subsequent chemo and 486 (74%) were able to return home. In a multivariate Cox model, higher monocyte count (HR 0.07; 95%CI 0.01-0.44) and albumin nadir (HR 0.93; 95%CI 0.91-0.96) decreased ICU hospitalization risk or death whereas both bacterial (HR 2.12; 95%CI 1.40-3.31) or fungal infection (HR 1.93; 95%CI 1.40-3.31) and concomitant Sars Cov2 infection (HR 2.93; 95%CI 1.41-6.33) increased it. Charlson index (HR: 1.00; 95%CI 0.91-1.10) and primary prophylactic G-CSF (HR 0.83; 95%CI 0.52-1.32) had no prognostic value.
Conclusions
Despite the use of primary prophylactic G-CSF, ICIN is an early event which leads to major complications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Assistance Publique - Hôpitaux de Paris Cancer Group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2053P - Dehospitalization through outpatient drug release in clinical pharmacy as a strategic cost-minimization action in a public oncology hospital in the Eastern Amazon: A quantitative analysis
Presenter: Kalysta Borges
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06